Nanoparticles have been a popular research topic in recent years for the many advantages they present in clinical applications. For example, in the context of Alzheimer's disease, they have been used to target amyloid-beta. And to test the effects of these nanoparticles on oligomerization and fibrillation processes, amyloid-beta is commonly used. However, the effects of the biomolecular corona, the biomolecules covering the surface of nanoparticles when in contact with biological fluids, on these pathological processes have been mostly ignored. In this study, the effects of the biomolecular corona derived either from human cerebrospinal fluid or plasma on amyloid-beta dynamics were investigated. The results showed that the interactions with amyloid-beta of the different biomolecular coronas triggered different outcomes of the nanoparticles in the aggregation of different amyloid-beta peptides. Plasma-derived biomolecular corona had less inhibitory effects on amyloid-beta 42 fibrillation than none or cerebrospinal fluid-originated corona, and the opposite was true for amyloid-beta 25-35 peptide. The researchers demonstrate that it is important to study the biological context where the nanoparticles will be used and the results shown here give new clues to future applications of nanoparticles and the potential profit of the environment to modulate their activity.
Biomolecular corona dictates Aβ fibrillation process
The IE from MS no longer understands current scripting languages, the latest main version (version 11) is from 2013 and has not been further developed since 2015.
Our recommendation: Use only the latest versions of modern browsers, for example Google Chrome, Mozilla Firefox or Microsofrt Edge, because only this guarantees you sufficient protection against infections and the correct display of websites!